Mastrapasqua Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$1.98M Sell
16,286
-185
-1% -$24.6K 0.23% 83
2023
Q2
$2.32M Sell
16,471
-20
-0.1% -$2.76K 0.26% 74
2023
Q1
$2.33M Sell
16,491
-1,525
-8% -$218K 0.29% 73
2022
Q4
$2.82M Sell
18,016
-20
-0.1% -$2.87K 0.37% 68
2022
Q3
$2.21M Buy
18,036
+330
+2% +$43.5K 0.32% 74
2022
Q2
$2.35M Sell
17,706
-630
-3% -$85.8K 0.32% 74
2022
Q1
$2.51M Sell
18,336
-1,069
-6% -$149K 0.28% 76
2021
Q4
$3.36M Buy
19,405
+95
+0.5% +$14.5K 0.33% 72
2021
Q3
$2.81M Buy
19,310
+10,640
+123% +$1.56M 0.31% 73
2021
Q2
$1.14M Buy
8,670
+367
+4% +$48.1K 0.12% 119
2021
Q1
$1.07M Buy
8,303
+1,260
+18% +$155K 0.12% 122
2020
Q4
$839K Sell
7,043
-2
-0% -$244 0.11% 115
2020
Q3
$807K Buy
7,045
+490
+7% +$57.9K 0.11% 116
2020
Q2
$747K Buy
+6,555
New +$695K 0.12% 116

Other funds holding DGX

Mastrapasqua Asset Management's DGX Position: Q3 2023 in Review

Mastrapasqua Asset Management reduced its Quest Diagnostics (DGX) stake by 1.1% in Q3 2023, selling an estimated $24.6K and leaving 16,286 shares worth $1.98M. The position accounts for 0.23% of the portfolio, ranked #83.

Mastrapasqua Asset Management first reported a position in DGX in Q2 2020 and has held it in 14 quarters since. The position peaked at $3.36M in Q4 2021. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

  • Mastrapasqua Asset Management held 16,286 shares of Quest Diagnostics worth $1.98M as of Q3 2023.
  • Mastrapasqua Asset Management sold 185 Quest Diagnostics shares in Q3 2023, an estimated $24.6K.
  • Quest Diagnostics made up 0.23% of Mastrapasqua Asset Management's portfolio in Q3 2023, its #83 holding.
  • Mastrapasqua Asset Management first reported a position in Quest Diagnostics in Q2 2020 and has held it in 14 quarters since.
  • Mastrapasqua Asset Management's Quest Diagnostics position peaked at $3.36M in Q4 2021.
  • 794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Mastrapasqua Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.